View Cart  

FDA Panel Supports Approval of Novo’s Long-Acting Insulin Despite Heart Concerns

A A
FDA advisers voted 8–4 Thursday in support of approval for Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg for Type 1 and Type 2 diabetes despite lingering worries about cardiovascular effects.

To View This Article:

Login

Subscribe To Drug Industry Daily